<SEC-DOCUMENT>0001144204-12-050318.txt : 20120910
<SEC-HEADER>0001144204-12-050318.hdr.sgml : 20120910
<ACCEPTANCE-DATETIME>20120910123507
ACCESSION NUMBER:		0001144204-12-050318
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20120910
FILED AS OF DATE:		20120910
DATE AS OF CHANGE:		20120910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		121082419

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v323370_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of September, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9;<B>XTL Biopharmaceuticals Ltd.&#9;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>85 Medinat Hayehudim St., Herzliya<BR>
Pituach, PO Box 4033,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Herzliya 46140, Israel</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&#9;<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;X&nbsp;&nbsp;&nbsp;&nbsp; </U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&#9;<U> ___</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes&#9;<U>&#9;</U>_____&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&#9;<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;X&nbsp;&nbsp;&nbsp;&nbsp; </U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated September 10, 2012 is hereby incorporated by reference into the registration statements
on Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the registration statements
on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL - Progress in the Acquisition of
Kitov Pharmaceuticals Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Below&nbsp;is
an English translation (from Hebrew) of an immediate report by XTL Biopharmaceuticals Ltd. as published on the Tel-Aviv Securities
Stock Exchange Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.gif" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Herzliya,
Israel &ndash; September 10, 2012 &ndash; </FONT>Following the immediate reports submitted by the Company on April&nbsp;15,
2012 and on June&nbsp;19, 2012 regarding the agreement, pursuant to which the Company will acquire the entire issued and
outstanding share capital of Kitov Pharmaceuticals Ltd., a company which is engaged in the research and development of
combination drugs (hereinafter respectively: &quot;<B>Kitov</B>&quot; and the &quot;<B>Agreement</B>&quot;), the Company
hereby announces that on September&nbsp;9, 2012, the board of directors of the Company and the board of directors of Kitov
approved an update to  the terms of the agreement, and subsequently thereto, the Company, Kitov and  Kitov&rsquo;s
shareholders have signed an updated agreement, the principal elements of which are detailed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">1.</TD><TD STYLE="text-align: justify">In exchange for receiving 100% of Kitov's issued and outstanding share capital, the
                                                            Company shall transfer to  Kitov&rsquo;s shareholders the following payments: (1) a cash payment of $140 thousand; (2) an issuance
                                                            of 8,709,052 ordinary shares of the Company; (3) an issuance of 218,728 warrants for the purchase of 218,728 shares of the
                                                            Company; (4) an issuance of 612,800 special warrants for the purchase of 612,800 shares of the Company (hereinafter: the
                                                            &quot;<B>special warrants</B>&quot;) (all the securities of the Company to be issued pursuant to Items 2-4 above will
                                                            comprise  approximately 4% of the Company's issued and outstanding share capital immediately following the aforesaid
                                                            issuance), and (5) certain additional payments to be made upon fulfillment of milestones that are dependent on the progress
                                                            in the development of  Kitov&rsquo;s drugs, which, jointly, comprise, in the aggregate, an amount of approximately $&nbsp;61
                                                            million (hereinafter: the &quot;<B>Milestone Payments</B>&quot;); provided that the Company has the exclusive right at any
                                                            time to convert any Milestone Payment payable to the Kitov&rsquo;s shareholders into shares of the Company, which will
                                                            constitute in the aggregate, up to approximately 38.5% of the Company's issued and outstanding share capital immediately upon
                                                            consummation of the transaction. The Milestone Payments will be in force for five years from the date of the Closing of the
                                                            aforesaid transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">2.</TD><TD STYLE="text-align: justify">Immediately upon the Closing of the transaction, Dr. Paul Waymack and an additional representative
on behalf of Kitov shall be appointed as directors of the Company, and the Company&rsquo;s board of directors shall recommend that Dr.
Paul Waymack  be appointed to serve as the chairman of the Company's board of directors. Furthermore, Dr. Waymack shall enter
into an agreement with the Company to provide services, including responsibility for the clinical and regulatory
development of all of the Company's products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">3.</TD><TD STYLE="text-align: justify">In  the event that the Company  completes a fundraising for an amount in excess of $4
                                                            million during a period of up to 18 months from the date of the Closing of this transaction, the Company will pay  Kitov's
                                                            shareholders an amount equal to $160 thousand and the special warrants will expire. If the Company does not
                                                            complete the aforesaid fundraising, Kitov's shareholders will be entitled to exercise the special warrants, and the Company
                                                            will not be obligated for the payment of the amount of $160 thousand, as detailed above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">4.</TD><TD STYLE="text-align: justify">If by  (i) November&nbsp;23, 2012, (ii) any other later date if extended by mutual
                                                            agreement of the parties, or (iii) a later date extended due to the timelines of the Israeli Tax Authority in relation to the
                                                            grant of the pre-ruling required for the transaction,  the Closing conditions for the transaction have not been
                                                            completed, each of the parties will have the right to terminate the agreement without the other party having a claim against
                                                            the terminating party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the consummation of the required  conditions and
evaluations, as well  as compliance with several additional conditions, it is the Company&rsquo;s intention to  publish an
immediate report for the purpose of consummating the material private placement,  in accordance with the Israeli Securities
Regulations (Private Placement of the Securities of a Listed Company), 2000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company will update its disclosure regarding the
agreement in the event of a material development through an immediate report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5in; text-align: justify; text-indent: 0.5in; background-color: white">Respectfully,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5in; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About XTL Biopharmaceuticals, Ltd. (&ldquo;XTL&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical
products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment
of multiple myeloma, schizophrenia, and hepatitis C. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL&rsquo;s
lead drug candidate, rHuEPO for the treatment of multiple myeloma blood cancer was granted an orphan drug designation from the
FDA. rHuEPO, has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world
for the treatment of severe anemia. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL is a public company traded on the Tel
Aviv Stock Exchange (TASE: XTL) and its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations, XTL Biopharmaceuticals
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080, Email: ir@xtlbio.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>XTL BIOPHARMACEUTICALS LTD.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Date: September 10, 2012&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ David
Grossman</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name:&#9; David
Grossman<BR>Title:&#9;Chief
Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=ABP`[`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````BP`[`(?____F[^\`,7,`A,X`*6/>YM[6YN^MYLZEM<4IG-8Q2HPAC-X(
M(6N<WN\0SN8`&6-SK=Y2K=[F$._F$&OF$*WF$"DI&1"M$.^M$&NM$*VM$"GF
M$,[F$$KF$(SF$`@(&1"M$,ZM$$JM$(RM$`@(0F-:K:524IQ[:UHI:UHQ6N][
M*5I[:QE[*1E[:YQ2:UI2*5I2:QE2*1D(6N]:WC$0WC%:G#$0G#$0[Z5::]Y:
M[V,0[V,0*=Y:*=XI2AE:K6,0K6,0*9Q:*9Q:[Z5[WA`QWA![G!`QG!`QSJ5[
M2EH(:UI["%I[2AE["!E[2IQ22EI2"%I22AE2"!E:2MY:SF,0SF,0"-Y:"-X(
M2AE:C&,0C&,0")Q:")Q:SJ5[C*4Q:Y002I1[Q=Y2E-Z<YJ76O:76O4*<O4*<
MO7/6O7/6O1"<O1`0:YREE*U[[^;FE._FE&OF0N_F0FLI&6OF0JWF0BGFE*WF
ME"DI&4*M0N^M0FNM0JVM0BFME.^ME&NME"FM:ZWF:^_F:VOF:ZWF:RFM:^^M
M:VNM:RE:[^80[^80G+5[C.8QSN:ME(SFE,[FE$KF0L[F0DKF0HSF0@CFE(SF
ME`@(&4*M0LZM0DJM0HRM0@BME,ZME$JME`BM:XSF:\[F:TKF:XSF:PBM:\ZM
M:TJM:PA:SN80G)1[K:6]YN]2<Y1[:]Y[[V,Q[V-[WC$QWC$Q*=Y[*=Y[G#$Q
MG#$I:QE[K6,QK6,Q*9Q[*9PQ[Z5[[Z5[2MY[SF,QSF,Q"-Y["-X(:QE[C&,Q
MC&,Q")Q[")Q[SJ76UN;6UM9:A)RUO:76[Z76[T*<[T*<[W/6[W/6[Q"<[Q`(
MG-XQ[^8QG+4QG)2]YJ7WO:7WO4*]O4*]O7/WO7/WO1"]O1"<O>:]O>8`<\XQ
M:\Y:[Q`0[Q!:K1`0K1`0SK4Q2LY:SA`0SA!:C!`0C!`0SI24M:4II>\A0G/W
M[Z7W[T+WYMZ][T*][W/W[W/W[Q"][Q``*7-:C+7WO=X(4L7>M>\I0E+>M<Y2
M<Z7W__\`A.;W_]X(_P#[O0L00"!!@P,+)D1X<.%`APTC*I1H<.)$B!8K8JS(
M<6-"B!XI8DP(H*3)DRA3JES)LJ7+ES!CRIQ9L@#,`-RZ\.N"(`#-GT"#"AT*
MP*;+``C8$5BJH(M/HE"C2OUIM"4"!4L%,#4UM:O7KR:KK@Q@+ZL`K0_X&0#+
MMFU0L2H-H")PMNX#5-S<ZMWKTFB``]R*!0X<P``_`O7J"KA;+(!@P:<`#S3`
M[=3CP8\M8]:<^;+F`P:>OB1XZE3H?C\+ES:`.JI1!"U0*/#BA9T7?L62TCV[
MU&D75+9=*&"'-T`7V5YFTUZ>7#GMV<ZA+R?.KLO:FV#")(BP373,?J>T)_^`
M<!VJ4;E+TQ,@@:"8/1(/"#P@H78;5O4$4`U$%1^___\`IL=83`&`,4`WB(`!
MU#:(=---`JRY9M)5\6G%%#?&H:*`"5T4\XXQZ=7#%`(`H$=7@"@&^(`7Y1UE
M8#<#@-':3-L\XV`"IW@GE%BF",!`7>MU45)N.0(`@5*[T45BB?PAEAA=(BHF
M)9!3`HE*,3$9`(&-"2B(THQC'9``(@-$T.*7)OD$9DIB!<"/5F>)J$!W)Q4S
M5V):T8<E`';VMY2(67TQI7J`1@ED?F>R5.```RP`AHXG/?4.2@:``0$8#4`*
MP*0TP775;GFV,"-9#"#&FP('F&3`;ZCP8TRKQO#_HR&H`K"C@*NOONHJ*E(B
MNJ9*_01`"J-=FL0I@02I&=6>)O73!9P"B,A.3R4=@%5=/PIYD@'%$--M,=P6
ML`VO0'[1H;?$>,OM58H1P"*!8-CHJ*8L_9HF49#::6JT`J"RE@$MF"4`"<8D
M.I8Q)"2IP)(`@,D-"GAJY2^!$!#K9<.%&1":CCKVXW%+R6J<+$O,GI04GE'V
MI!N0"QM[5`O0$J``5RJ=H@#*B,(4;+S=.%J2`0U`$,'08&`**6D--%`D2@49
ML`T80Q,-1F@JB=6:`?:4BBT_"/":I`#:9LGKCUI-N]*G5E+]D@'#/MA=`Q$D
MP"BC"SP3!AA+FQ1>-`N0_Y=2I0G(/?<"`VPW]9IP33@7D.Q\P<ZA$[<$9@'V
MM-M4LR?9#.I=!JM4()>81N#@W`?"6&8#8!Y@8S<1G%+24Z?$?2#II3,:1MY%
MC84`M+R!6D_+,Q%CC(^\F:T2VKQ%/EK%_@0N-R+;19W`,W.W?M(V@IMYT@$1
MS&UW!!"0$C?U,%IO4LF4(DPKXTZ-%BG,4!+`#@2OH\2-%[N)^"YVU-?-*'<Y
M"D!D($`X?["N/*=(@#_*Y+J?=8]1SX#``0XB0`C(;8%A*$_B3':M02E/)H89
M6/$8AI(#*"5M!!K6`@?PC,.5!#6%46'A+M8`ZI7I.I^#49<*$JD""2Y&3]E@
ML_^Z<$++D5`FE..7M-:PDF+<+$XYPPX$!W"[E6BI>M=I@`)O6)+8'2B"G5L4
M!AM0$Y=P8W&"JHL]Z.42X3&`;#*C7TKZ81]0(8J-D2)%`5M(KWZP@7"%(R,`
MM%@^UO3#0`O$T4G6!+>Y>4F(JBI+K_!2/YD$`&909(<Z2G*L:N'/+A\$F8$.
MI$B6&"`"7*)3`A>HB+4LBH40P.,K%Q`!GT"R842<DHC6Z+YMO0F."F#B\3JH
M%;6D$)#:N]>VNM>-%J(&>_];BQ>;=['6>*<?6DSD6A)WK#,*C''4\IP5^4$"
MQLDQ)4[,7W[0=ZQC[6R%R60:QBK6J%H"(($#\(?V\!G_R)?@\T%DA*1[O@FY
MO+BL+[\<X4KJ""2UV"LEPH+@HT!&B@1TPQ^QQ*8-:TG'[#6P)>')9P("NLAF
MK8Q*=1%1^T#X+"A>3B764N?^U@8&0$+@H:_CV3/LB4]]KD6+MONH*161R&WD
MKI(E&9?`;/4X`7QA*<9[(;!4-3:%(A4`R)-8YR`*!@/N4)2S>Q0VD;D6:#)P
M;8(;Z5&9U@6!U<,>ZJA<Q-;)TIC-K(F?C%841S/*".(4`#YLICV!6B:?`)5U
M1HW4W])*4J:9`BMXDE]W3@JGE4(4)<5(:-F.:!*&)@^'+F&;(_%X2J].%*@^
MO><#U2HYU"HR<<4P@1T)YDJO_[%L&]9LR:I2*C-M=1(`,85B*%?BL6U\,9YQ
MB8!I44-8[9URM"X!0_:VR;2RV!%X6"7F>HPAEM]2E7B;/9MVC7G92D:4<!"Z
M*FHT2JPL6C2U8N2B*9DY@%BN%;"438QE`?`L=8*-7L?:;9+FAU<[>H$G"$BP
M@A>\X#`\(Y$R&LLH"UN2;`Z@E15.ZT0]9]:1HD8LWK1C*$\QE_PQ0`$&;4EF
M11A>E6RCB'51@(QG3&,:VTH-U%M@!`3Y)>D2"[<9CJ8#;62W5$&4G_*MBG'V
M5;:PI6EW$9,8'@$+L\3(R<EURNNA4I0>-;!PHYGR24$"L(T'RO>>%XPGDG<\
M,H+`S?^&'BYC22B+&/)B%A5:*Q[-3$G.`3/,.UGM%9P,!44!X./+<^M2TDZQ
MC2U5[P`S,JN9K&G6&6XC,D^3FPXW?-00GTA^#/OMBTTEH@>@V"?>+9$Q&/"`
M4E=G)=Q@1X5B]J1Z1$E$N*:+EYLWM$0[SX8S!%,-8;2.%OEP=LUS7CXW[1V;
M&`<^V/JOHNRA%!+\B!)@VVHQ5OTC^$05)0C`G[7+R6)RF[LN"1.`ET_'O04X
MZ-W$BL`$44)8\H")S*B<W>AT&($(G\3973!&"^S1A8!WR"7%Z$(+=D)P8W3!
M:I%"@,%;X'`C0]04"]=)P0>N<()SG.,:MT<)('"I?T'->0G_B$:_A1H62UT*
M4OVHE`51;KA3_,HO!`%LSM>TIH($2^<Y5PFGDA6L/@+V'<'R&`7'S/2B`U;G
M3G^=`0ZPC08<($</+;K/@16LI%4=-#RLVDO^VDN9I/HK'OLYFG3&];2SY)8L
M.3M?YB[+U/S;)62?N][G#O>]^_WO=P<\X*>L][Y#A?!_1WQ;T"?XQBO>*X:7
M9^,G/Y7(*XKR4Y'[5RR/^<[#1/-R]KSH]<+YT9N>)HPG"N@M.9353][UIX_]
M3$J?>-D/A?:VSSUFWV&`=Q0@``4H@.^#3_SB&S_XO!>^`91__.8[W_?`Y[WT
<G=_\WB]_^,(G/O:3SWSJ>[_XW#]^!/()$A``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
